Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer.

The identification of tumor suppressor genes has classically depended on their localization within recurrent regions of loss of heterozygosity. According to Knudson's two-hit hypothesis, the remaining allele is lost, either genetically or, more recently identified, through epigenetic events. To date, retrospective analyses have determined promoter methylation as a common alternative alteration in cancer cells to silence cancer-related genes. Here we report an application of restriction landmark genomic scanning that allows for DNA methylation profiling along a region of recurrent loss of heterozygosity at chromosome 6q23-q24. This approach resulted in the identification of a tumor suppressor gene, TCF21, which is frequently lost in human malignancies. We demonstrate that TCF21 is expressed in normal lung airway epithelial cells and aberrantly methylated and silenced in the majority of head and neck squamous cell carcinomas and non-small-cell lung cancers analyzed. TCF21 is known to regulate mesenchymal cell transition into epithelial cells, a property that has been shown to be deficient in carcinomas. We further demonstrate that exogenous expression of TCF21 in cells that have silenced the endogenous TCF21 locus resulted in a reduction of tumor properties in vitro and in vivo.

[1]  K Autio,et al.  DNA copy number losses in human neoplasms. , 1999, The American journal of pathology.

[2]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[3]  E. Speel,et al.  Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. , 2001, The American journal of pathology.

[4]  C. Rinker-Schaeffer,et al.  Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.

[5]  J. Rossant,et al.  The basic-helix-loop-helix protein pod1 is critically important for kidney and lung organogenesis. , 1999, Development.

[6]  I. Petersen,et al.  Genomic alterations associated with malignancy in head and neck cancer , 1998, Head & neck.

[7]  A. Berns,et al.  Mouse models for human lung cancer. , 2005, Genes & development.

[8]  E. Olson,et al.  Control of Facial Muscle Development by MyoR and Capsulin , 2002, Science.

[9]  M. Takagi,et al.  Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-associated oral carcinoma in a Vietnamese non-smoking/non-drinking female population. , 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[10]  J. Mark,et al.  Partial 6q deletion in a human salivary gland adenocarcinoma. , 1989, Cancer genetics and cytogenetics.

[11]  G. Prindull,et al.  Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. , 2004, Blood.

[12]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[13]  E. Olson,et al.  The basic helix-loop-helix transcription factor capsulin controls spleen organogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Perrimon,et al.  Apicobasal polarization: epithelial form and function. , 2003, Current opinion in cell biology.

[15]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[16]  M. Takata,et al.  Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. , 2001, Cancer research.

[17]  J. Minna,et al.  Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Olson,et al.  Capsulin: a novel bHLH transcription factor expressed in epicardial progenitors and mesenchyme of visceral organs , 1998, Mechanisms of Development.

[19]  C. Plass,et al.  Bone morphogenetic protein 3B silencing in non-small-cell lung cancer , 2004, Oncogene.

[20]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[21]  A. Kiemer,et al.  Identification of genes involved in epithelial-mesenchymal transition and tumor progression , 2001, Oncogene.

[22]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[23]  Colin C. Collins,et al.  Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors , 2002, Nature Genetics.

[24]  K. Chada,et al.  Expression of Mesenchyme-Specific Gene HMGA2 in Squamous Cell Carcinomas of the Oral Cavity , 2004, Cancer Research.

[25]  J. Shannon,et al.  Epithelial-mesenchymal interactions in the developing lung. , 2004, Annual review of physiology.

[26]  J. Mark,et al.  6q- and loss of the Y chromosome--two common deviations in malignant human salivary gland tumors. , 1986, Cancer genetics and cytogenetics.

[27]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[28]  Marshall W. Anderson,et al.  A major lung cancer susceptibility locus maps to chromosome 6q23-25. , 2004, American journal of human genetics.

[29]  C. Morelli,et al.  A human melanoma metastasis‐suppressor locus maps to 6q16.3‐q23 , 2000, International journal of cancer.

[30]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[31]  A. Bukovsky,et al.  Association of mesenchymal cells and immunoglobulins with differentiating epithelial cells , 2001, BMC Developmental Biology.

[32]  R. Happonen,et al.  Specificity of 6q- markers and other recurrent deviations in human malignant salivary gland tumors. , 1988, Anticancer research.

[33]  C. Rinker-Schaeffer,et al.  What defines a useful marker of metastasis in human cancer? , 1999, Journal of the National Cancer Institute.

[34]  J. Minna,et al.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. , 2000, Cancer research.

[35]  K. Parker,et al.  Disrupted gonadogenesis and male-to-female sex reversal in Pod1 knockout mice , 2004, Development.

[36]  Y. Hayashizaki,et al.  An expanded system of restriction landmark genomic scanning (RLGS Ver. 1.8) , 1995, Electrophoresis.

[37]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[38]  B. Boyer,et al.  Induction and regulation of epithelial-mesenchymal transitions. , 2000, Biochemical pharmacology.

[39]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[40]  G. Pfeifer,et al.  Methylation of the RASSF1A Gene in Human Cancers , 2002, Biological chemistry.

[41]  C. R. Leemans,et al.  Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. , 2004, Journal of the National Cancer Institute.

[42]  I. Tomlinson,et al.  Loss of heterozygosity analysis: Practically and conceptually flawed? , 2002, Genes, chromosomes & cancer.

[43]  Masataka Nakamura,et al.  Basic Helix-Loop-Helix Transcription Factor Epicardin/Capsulin/Pod-1 Suppresses Differentiation by Negative Regulation of Transcription* , 2003, The Journal of Biological Chemistry.

[44]  B. Weissman,et al.  Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. , 1994, Oncogene.